(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 November 2015 (05.11.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/168666 A2

(51) International Patent Classification:
C07K 14/71 (2006.01)

(21) International Application Number:
PCT/US2015/028966

(22) International Filing Date:
2 May 2015 (02.05.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/988,131 2 May 2014 (02.05.2014) US
62/114,575 10 February 2015 (10.02.2015) US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 500 Kendall Street, Cambridge, MA 02142 (US).

(72) Inventors: **SCARIA, Abraham**; C/o Sanofi, 55 Corporate Drive, Mail Code: 55a-505a, Bridgewater, NJ 08807 (US). **SULLIVAN, Jennifer**; C/o Sanofi, 55 Corporate Drive, Mail Code: 55a-505a, Bridgewater, NJ 08807 (US). **STANEK, Lisa, M.**; C/o Sanofi, 55 Corporate Drive, Mail Code: 55a-505a, Bridgewater, NJ 08807 (US).

(74) Agents: **ZHOU, Jie** et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105-2482 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*


Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

[Continued on next page]

(54) Title: AAV VECTORS FOR RETINAL AND CNS GENE THERAPY

FIG. 8



(57) Abstract: Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of rAAV particles. Further provided herein are improved recombinant adeno-associated virus (rAAV) (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of disorders of the CNS. The invention provides methods for delivering the rAAV to the CNS, methods for treating disorders of the CNS with improved compositions of rAAV particles, and kits for delivering the rAAV to the CNS and/or treating a CNS disorder.

WO 2015/168666 A2

— *with sequence listing part of description (Rule 5.2(a))*